ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the 13 Best Low Risk High Growth Stocks to Buy. The company witnesses ...

ADMA Biologics, Inc.’s ADMA is witnessing a phenomenal run this year. Its shares have surged a whopping 262.1% in the year so far against the industry’s decline of 2.1%. The stock has been ...

We expect investors to focus on the sales performance of ADMA Biologics, Inc.’s ADMA portfolio of marketed products and other pipeline updates when it reports second-quarter 2024 results.

On ADMA's fourth-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.

ADMA Biologics is a plasma pure play. This company earns most of its revenue marketing FDA-approved products made from plasma. ADMA Biologics also runs its own plasma collection facilities and ...

About ADMA Biologics, Inc. (ADMA) ADMA Biologics is a commercial biopharmaceutical company dedicated to marketing and developing plasma-derived, human immune globulin products for immunodeficient ...

The company has three commercialized products, Asceniv, Bivigam, ... Asceniv is a driving force for ADMA Biologics. The company has reported robust revenue numbers for the fourth quarter of 2019.

We recently published a list of 10 Stocks Take A Shocking Nosedive. ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the worst-performing stocks on Thursday. ADMA Biologics saw its share prices decline by ...

ADMA Biologics shares were 15% higher, at $25.25, ... Its products infuse people with primary immunodeficiency with the virus-blocking antibodies their own bodies can't make.

ADMA showed strong growth in 2019, but shares remain 50% off recent highs. ADMA’s outlook for 2020 and beyond appears promising, but it is not without risks.